Jiang et al. reported that the single-dose FAK inhibition of VS-4718 greatly obstacles the tumor progression, increases two-folds survival rate in a human LSL-Kras (G12D) KPC mouse model [69]. This evidence concerns the gene PTK2 and neoplasm.